PharmaEssentia Corporation announced appointment of Lih-Ling Lin as Chief Scientific Officer, effective from August 1, 2022. Name, title, and resume of the new position holder: Lih-Ling Lin /Chief Scientific Officer /The Head of Checkpoint immunology cluster in Immunology and Inflammation Research Area at Sanofi.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
486 TWD | -1.42% |
|
+1.04% | +40.46% |
May. 27 | Pharmaessentia Corporation Announces Term Expiration of Their Fourth Remuneration Committee | CI |
May. 27 | Pharmaessentia Corporation Announces Changes to Members of Third Audit Committee | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.46% | 5.05B | |
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.72B | |
-18.26% | 20.82B | |
-18.47% | 16.66B | |
-42.36% | 16.36B | |
-14.23% | 16.19B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- 6446 Stock
- News PharmaEssentia Corporation
- PharmaEssentia Corporation Announces Appointment of Lih-Ling Lin as Chief Scientific Officer